Donor CAR-T cells for B-cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years or older
- Have B-cell acute lymphoblastic leukemia that returned or didn't respond to treatment
- Cancer cells must show a protein called CD19
- Liver, kidney, and blood test results must be within certain limits
- Must not have active hepatitis B, C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.